Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb FOCUS study of Fremanezumab in Adults with Migraine
Jerusalem, 2nd July 2019 — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today is proud to present the FOCUS exploratory endpoints results at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway from June 29th - July 2nd, 2019.